Singular Genomics Systems, Inc. provided unaudited revenue guidance for the fourth quarter of 2023. For the quarter, the company revenue is expected to be approximately $1.0 million, representing growth of approximately 31% compared to $765,000 during the fourth quarter of 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4118 USD | -8.06% | -0.31% | -10.50% |
03-20 | UBS Adjusts Singular Genomics Systems Price Target to $0.50 From $0.40, Maintains Neutral Rating | MT |
03-18 | Transcript : Singular Genomics Systems, Inc., Q4 2023 Earnings Call, Mar 18, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.50% | 30.51M | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- OMIC Stock
- News Singular Genomics Systems, Inc.
- Singular Genomics Systems, Inc. Provides Unaudited Revenue Guidance for the Fourth Quarter of 2023